Characterization of the Variability of Epstein-Barr Virus Genes in Nasopharyngeal Biopsies: Potential Predictors for Carcinoma Progression
Open Access
- 12 April 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (4) , e0153498
Abstract
Epstein-Barr virus (EBV) infection is a significant factor in the pathogenesis of nasopharyngeal carcinoma, especially in the undifferentiated carcinoma of nasopharyngeal type (UCNT, World Health Organization type III), which is the dominant histopathological type in high-risk areas. The major EBV oncogene is latent membrane protein 1 (LMP1). LMP1 gene shows variability with different tumorigenic and immunogenic potentials. EBV nuclear antigen 1 (EBNA1) regulates progression of EBV-related tumors; however, the influence of EBNA1 sequence variability on tumor pathogenesis is controversial. The aims of this study were to characterize polymorphisms of EBV genes in non-endemic nasopharyngeal carcinoma biopsies and to investigate potential sequence patterns that correlate with the clinical presentation of nasopharyngeal carcinoma. In total, 116 tumor biopsies of undifferentiated carcinoma of nasopharyngeal type (UCNT), collected from 2008 to 2014, were evaluated in this study. The genes EBNA2, LMP1, and EBNA1 were amplified using nested-PCR. EBNA2 genotyping was performed by visualization of PCR products using gel electrophoresis. Investigation of LMP1 and EBNA1 included sequence, phylogenetic, and statistical analyses. The presence of EBV DNA was significantly distributed between TNM stages. LMP1 variability showed six variants, with the detection of the first China1 and North Carolina variants in European nasopharyngeal carcinoma biopsies. Newly discovered variants Srb1 and Srb2 were UCNT-specific LMP1 polymorphisms. The B95-8 and North Carolina variants are possible predictors for favorable TNM stages. In contrast, deletions in LMP1 are possible risk factors for the most disfavorable TNM stage, independent of EBNA2 or EBNA1 variability. A newly discovered EBNA1 subvariant, P-thr-sv-5, could be a potential diagnostic marker, as it represented a UCNT-specific EBNA1 subvariant. A particular combination of EBNA2, LMP1, and EBNA1 polymorphisms, type 1/Med/P-thr was identified as a possible risk factor for TNM stage IVB or progression to the N3 stage.Keywords
Funding Information
- Ministry of Education, Science and Technological Development, Republic of Serbia (175073)
This publication has 45 references indexed in Scilit:
- Tyrosylprotein Sulfotransferase-1 and Tyrosine Sulfation of Chemokine Receptor 4 Are Induced by Epstein-Barr Virus Encoded Latent Membrane Protein 1 and Associated with the Metastatic Potential of Human Nasopharyngeal CarcinomaPLOS ONE, 2013
- Variations of Epstein-Barr Virus Nuclear Antigen 1 in Epstein-Barr Virus-Associated Gastric Carcinomas from Guangzhou, Southern ChinaPLOS ONE, 2012
- The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC)Seminars in Cancer Biology, 2012
- Non-viral environmental risk factors for nasopharyngeal carcinoma: A systematic reviewSeminars in Cancer Biology, 2012
- Analysis of EBNA-1 and LMP-1 variants in diseases associated with EBV infection in Chinese childrenVirology Journal, 2012
- The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: A need for reappraisalVirus Research, 2009
- An Update on Epstein-Barr Virus and Nasopharyngeal CarcinogenesisHead and Neck Pathology, 2007
- EBV-associated nasopharyngeal carcinomas: from epidemiology to virus-targeting strategiesTrends in Microbiology, 2004
- Analyses of Epstein‐Barr virus latent membrane protein‐1 in Malaysian nasopharyngeal carcinoma: High prevalence of 30‐bp deletion, Xho1 polymorphism and evidence of dual infectionsJournal of Medical Virology, 2002
- An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cellsCell, 1985